Marc Puigvehi

Marc Puigvehi

Auto-generated profile, based on publicly available information

Marc Puigvehi

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MGMarina Ruiz de Galarreta
Marina Ruiz de Galarreta
EBErin Bresnahan
Erin Bresnahan
PMPedro Molina-Sánchez
Pedro Molina-Sánchez
KLKatherine E. Lindblad
Katherine E. Lindblad
BMBarbara Maier
Barbara Maier
ALAmaia Lujambio
Amaia Lujambio
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983


26 September 2017 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MPMarc Puigvehí
Marc Puigvehí
TBTeresa Broquetas
Teresa Broquetas
SCSusanna Coll
Susanna Coll
MGMontserrat Garcia‐Retortillo
Montserrat Garcia‐Retortillo
NCNuria Cañete
Nuria Cañete
JCJosé A. Carrión
José A. Carrión

27 August 2014 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
CACarrión
Carrión
JCJosé A. Carrión
José A. Carrión
MPM. Puigvehí
M. Puigvehí
SCS. Coll
S. Coll
MGM. Garcia‐Retortillo
M. Garcia‐Retortillo
RSR. Solà
R. Solà

1 December 2012 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
MPManuel Pera
Manuel Pera
LMLucia Márquez
Lucia Márquez
JDJosep M. Dedeu
Josep M. Dedeu
JSJuan Sánchez
Juan Sánchez
MGMar Garcia
Mar Garcia
MPMarc Puigvehí
Marc Puigvehí

10 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JAJordi Abril-Fornaguera
Jordi Abril-Fornaguera
LTLaura Torrens
Laura Torrens
CACarmen Andreu-Oller
Carmen Andreu-Oller
JCJuan Carrillo-Reixach
Juan Carrillo-Reixach
ARAlex Rialdi
Alex Rialdi
JLJosep M. Llovet
Josep M. Llovet
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of molecular therapies in preclinical models of HB. Paired tumor and adjacent tissues from 31 HBs and a validation set of 50 HBs were analyzed using RNA-seq, SNP, and methylation arrays. IGF2 overexpression was identified as the top targetable HB driver, present in 71% of HBs (22/31). IGF2high tumors displayed progenitor cell features and shorter recurrence-free survival. IGF2 overexpression was associated in 91% of cases with fetal promoter hypomethylation, ICR1 deregulation, 11p15.5 loss of heterozygosity or miR483-5p overexpression. The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. The combination of xentuzumab with cisplatin showed strong synergistic antitumor effects in organoids and in IGF2high cell lines. In mice (n = 55), the combination induced a significant decrease in tumor volume and improved survival compared with cisplatin alone. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.